-
1
-
-
51849107500
-
Drug interactions involving combination antiretroviral therapy and other anti-infective agents: Repercussions for resource-limited countries
-
Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis. 2008;7: 948-961.
-
(2008)
J Infect Dis
, vol.7
, pp. 948-961
-
-
Dooley, K.E.1
Flexner, C.2
Andrade, A.S.3
-
2
-
-
33846886738
-
PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine
-
Li T, Chen W, Chiang JY. PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J Lipid Res. 2007;2:373-384.
-
(2007)
J Lipid Res
, vol.2
, pp. 373-384
-
-
Li, T.1
Chen, W.2
Chiang, J.Y.3
-
3
-
-
39749171761
-
Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response
-
Moreau A, Vilarem MJ, Maurel P, et al. Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol Pharm. 2008;1:35-41.
-
(2008)
Mol Pharm
, vol.1
, pp. 35-41
-
-
Moreau, A.1
Vilarem, M.J.2
Maurel, P.3
-
4
-
-
0035823528
-
Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR
-
Dussault I, Lin M, Hollister K, et al. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem. 2001;36: 33309-33312.
-
(2001)
J Biol Chem
, vol.36
, pp. 33309-33312
-
-
Dussault, I.1
Lin, M.2
Hollister, K.3
-
5
-
-
0035987895
-
CYP3A4 induction by drugs: Correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes
-
Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002;7: 795-804.
-
(2002)
Drug Metab Dispos
, vol.7
, pp. 795-804
-
-
Luo, G.1
Cunningham, M.2
Kim, S.3
-
6
-
-
0035029345
-
Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors
-
Huang L, Wring SA, Woolley JL, et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos. 2001;5:754-760.
-
(2001)
Drug Metab Dispos
, vol.5
, pp. 754-760
-
-
Huang, L.1
Wring, S.A.2
Woolley, J.L.3
-
7
-
-
44149109915
-
Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: Studies with anti-human immunodeficiency virus protease inhibitors
-
Gupta A, Mugundu GM, Desai PB, et al. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos. 2008;6: 1172-1180.
-
(2008)
Drug Metab Dispos
, vol.6
, pp. 1172-1180
-
-
Gupta, A.1
Mugundu, G.M.2
Desai, P.B.3
-
8
-
-
6344240478
-
Induction of CYP3A4 by efavirenz in primary human hepatocytes: Comparison with rifampin and phenobarbital
-
Hariparsad N, Nallani SC, Sane RS, et al. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004;11:1273-1281.
-
(2004)
J Clin Pharmacol
, vol.11
, pp. 1273-1281
-
-
Hariparsad, N.1
Nallani, S.C.2
Sane, R.S.3
-
9
-
-
15244350599
-
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients
-
Fellay J, Marzolini C, Decosterd L, et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol. 2005;12:865-873.
-
(2005)
Eur J Clin Pharmacol
, vol.12
, pp. 865-873
-
-
Fellay, J.1
Marzolini, C.2
Decosterd, L.3
-
10
-
-
0034785945
-
The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants
-
Zhang J, Kuehl P, Green ED, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001;7:555-572.
-
(2001)
Pharmacogenetics
, vol.7
, pp. 555-572
-
-
Zhang, J.1
Kuehl, P.2
Green, E.D.3
-
11
-
-
34247624633
-
Identification of NR1I2 genetic variation using resequencing
-
King CR, Xiao M, Yu J, et al. Identification of NR1I2 genetic variation using resequencing. Eur J Clin Pharmacol. 2007;6:547-554.
-
(2007)
Eur J Clin Pharmacol
, vol.6
, pp. 547-554
-
-
King, C.R.1
Xiao, M.2
Yu, J.3
-
12
-
-
37549010733
-
Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression
-
Lamba J, Lamba V, Strom S, et al. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos. 2008;1: 169-181.
-
(2008)
Drug Metab Dispos
, vol.1
, pp. 169-181
-
-
Lamba, J.1
Lamba, V.2
Strom, S.3
-
13
-
-
0034777488
-
Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4
-
Hustert E, Zibat A, Presecan-Siedel E, et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos. 2001;11:1454-1459.
-
(2001)
Drug Metab Dispos
, vol.11
, pp. 1454-1459
-
-
Hustert, E.1
Zibat, A.2
Presecan-Siedel, E.3
-
14
-
-
53349160769
-
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-.T) with reduced concentrations of unboosted atazanavir
-
Siccardi M, D'Avolio A, Baietto L, et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-.T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis. 2008;9:1222-1225.
-
(2008)
Clin Infect Dis
, vol.9
, pp. 1222-1225
-
-
Siccardi, M.1
D'Avolio, A.2
Baietto, L.3
-
15
-
-
19944428456
-
Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study
-
Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
-
(2004)
AIDS
, vol.18
, pp. 2391-2400
-
-
Haas, D.W.1
Ribaudo, H.J.2
Kim, R.B.3
-
16
-
-
15944414161
-
An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children
-
Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS. 2005;4:371-380.
-
(2005)
AIDS
, vol.4
, pp. 371-380
-
-
Saitoh, A.1
Singh, K.K.2
Powell, C.A.3
-
17
-
-
0037022006
-
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study
-
Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;9300:30-36.
-
(2002)
Lancet
, vol.9300
, pp. 30-36
-
-
Fellay, J.1
Marzolini, C.2
Meaden, E.R.3
-
18
-
-
27944460707
-
Pharmacogenetics of long-term responses to antiretroviral regimens containing eavirenz and/or nelfinavir: An Adult Aids Clinical Trials Group Study
-
Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing eavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005;11: 1931-1942.
-
(2005)
J Infect Dis
, vol.11
, pp. 1931-1942
-
-
Haas, D.W.1
Smeaton, L.M.2
Shafer, R.W.3
-
19
-
-
17644414659
-
Influence of 516G.T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects
-
Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G.T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005;9:1358-1361.
-
(2005)
Clin Infect Dis
, vol.9
, pp. 1358-1361
-
-
Rodriguez-Novoa, S.1
Barreiro, P.2
Rendon, A.3
-
20
-
-
20244364148
-
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
-
Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;1:1-5.
-
(2005)
Pharmacogenet Genomics
, vol.1
, pp. 1-5
-
-
Rotger, M.1
Colombo, S.2
Furrer, H.3
-
21
-
-
26244454187
-
Functional analysis of four naturally occurring variants of human constitutive androstane receptor
-
Ikeda S, Kurose K, Jinno H, et al. Functional analysis of four naturally occurring variants of human constitutive androstane receptor. Mol Genet Metab. 2005;1-2:314-319.
-
(2005)
Mol Genet Metab
, vol.1-2
, pp. 314-319
-
-
Ikeda, S.1
Kurose, K.2
Jinno, H.3
-
22
-
-
32044444072
-
The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease
-
Dring MM, Goulding CA, Trimble VI, et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology. 2006;2:341-348.
-
(2006)
Gastroenterology
, vol.2
, pp. 341-348
-
-
Dring, M.M.1
Goulding, C.A.2
Trimble, V.I.3
-
23
-
-
33747085521
-
Cyp3A4 Cyp3A5 and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients
-
Roy JN, Barama A, Poirier C, et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics. 2006;9:659-665.
-
(2006)
Pharmacogenet Genomics
, vol.9
, pp. 659-665
-
-
Roy, J.N.1
Barama, A.2
Poirier, C.3
-
24
-
-
0034948077
-
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
-
Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001;5:399-415.
-
(2001)
Pharmacogenetics
, vol.5
, pp. 399-415
-
-
Lang, T.1
Klein, K.2
Fischer, J.3
-
25
-
-
49649103848
-
The steady-state pharmaco-kinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors
-
von HN, Babacan E, Lennemann T, et al. The steady-state pharmaco-kinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother. 2008;3: 579-582.
-
(2008)
J Antimicrob Chemother
, vol.3
, pp. 579-582
-
-
Von Hn Babacan, E.1
Lennemann, T.2
-
26
-
-
33847672711
-
Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers
-
Sekar VJ, Lefebvre E, De PE, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother. 2007;3:958-961.
-
(2007)
Antimicrob Agents Chemother
, vol.3
, pp. 958-961
-
-
Sekar, V.J.1
Lefebvre, E.2
De, P.E.3
-
27
-
-
34548299142
-
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers
-
Luber AD, Brower R, Kim D, et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med. 2007;7:457-464.
-
(2007)
HIV Med
, vol.7
, pp. 457-464
-
-
Luber, A.D.1
Brower, R.2
Kim, D.3
-
28
-
-
0034801355
-
Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers
-
Saah AJ, Winchell GA, Nessly ML, et al. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Chemother. 2001;10:2710-2715.
-
(2001)
Antimicrob Agents Chemother
, vol.10
, pp. 2710-2715
-
-
Saah, A.J.1
Winchell, G.A.2
Nessly, M.L.3
-
29
-
-
41849146368
-
Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir
-
Klein CE, Chiu YL, Cai Y, et al. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. J Clin Pharmacol. 2008;5:553-562.
-
(2008)
J Clin Pharmacol
, vol.5
, pp. 553-562
-
-
Klein, C.E.1
Chiu, Y.L.2
Cai, Y.3
-
30
-
-
25144491177
-
The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients
-
Justesen US, Hansen IM, Andersen AB, et al. The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients. HIV Med. 2005;5: 334-340.
-
(2005)
HIV Med
, vol.5
, pp. 334-340
-
-
Justesen, U.S.1
Hansen, I.M.2
Andersen, A.B.3
-
31
-
-
33750570685
-
Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir
-
Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;3:278-283.
-
(2006)
J Acquir Immune Defic Syndr
, vol.3
, pp. 278-283
-
-
Kearney, B.P.1
Mathias, A.2
Mittan, A.3
-
32
-
-
27844564302
-
Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers
-
Bittner B, Riek M, Holmes B, et al. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers. Antivir Ther. 2005;7:803-810.
-
(2005)
Antivir Ther
, vol.7
, pp. 803-810
-
-
Bittner, B.1
Riek, M.2
Holmes, B.3
-
33
-
-
1542409142
-
A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients
-
McCallister S, Valdez H, Curry K, et al. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;4:376-382.
-
(2004)
J Acquir Immune Defic Syndr
, vol.4
, pp. 376-382
-
-
McCallister, S.1
Valdez, H.2
Curry, K.3
-
35
-
-
17144399255
-
Pharmacokinetic profiling and bioequivalence evaluation of 2 lamivudine tablet formulations after single oral administration in healthy human Indian volunteers
-
Narang VS, Lulla A, Malhotra G, et al. Pharmacokinetic profiling and bioequivalence evaluation of 2 lamivudine tablet formulations after single oral administration in healthy human Indian volunteers. J Acquir Immune Defic Syndr. 2005;5:566-569.
-
(2005)
J Acquir Immune Defic Syndr
, vol.5
, pp. 566-569
-
-
Narang, V.S.1
Lulla, A.2
Malhotra, G.3
-
36
-
-
12944284655
-
Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers
-
Droste JA, Verweij-van Wissen CP, Kearney BP, et al. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2005;2:680-684.
-
(2005)
Antimicrob Agents Chemother
, vol.2
, pp. 680-684
-
-
Droste, J.A.1
Verweij-Van Wissen, C.P.2
Kearney, B.P.3
-
37
-
-
33646404628
-
Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects
-
Marier JF, Manthos H, Kebir S, et al. Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects. Int J Clin Pharmacol Ther. 2006;5:240-246.
-
(2006)
Int J Clin Pharmacol Ther
, vol.5
, pp. 240-246
-
-
Marier, J.F.1
Manthos, H.2
Kebir, S.3
-
38
-
-
37349046483
-
Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects
-
Liu P, Foster G, LaBadie RR, et al. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol. 2008;1:73-84.
-
(2008)
J Clin Pharmacol
, vol.1
, pp. 73-84
-
-
Liu, P.1
Foster, G.2
Labadie, R.R.3
-
39
-
-
34548515995
-
Bioequivalence study of two nevirapine tablet formulations in human-immunodeficiency-virus-infected patients
-
Tarinas A, Tapanes RD, Gonzalez D, et al. Bioequivalence study of two nevirapine tablet formulations in human-immunodeficiency-virus-infected patients. Farm Hosp. 2007;3:165-168.
-
(2007)
Farm Hosp
, vol.3
, pp. 165-168
-
-
Tarinas, A.1
Tapanes, R.D.2
Gonzalez, D.3
-
40
-
-
46349097362
-
Reviews of anti-infective agents: Maraviroc: The first of a new class of antiretroviral agents
-
MacArthur RD, Novak RM. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis. 2008;2: 236-241.
-
(2008)
Clin Infect Dis
, vol.2
, pp. 236-241
-
-
MacArthur, R.D.1
Novak, R.M.2
-
41
-
-
33845907631
-
A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background
-
Haan C, Behrmann I. A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. J Immunol Methods. 2007;1-2:11-19.
-
(2007)
J Immunol Methods
, vol.1-2
, pp. 11-19
-
-
Haan, C.1
Behrmann, I.2
-
42
-
-
13444269543
-
Haploview: Analysis and visualization of LD and haplotype maps
-
Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;2:263-265.
-
(2005)
Bioinformatics
, vol.2
, pp. 263-265
-
-
Barrett, J.C.1
Fry, B.2
Maller, J.3
-
43
-
-
4444367508
-
Haplotype reconstruction from genotype data using Imperfect Phylogeny
-
Halperin E, Eskin E. Haplotype reconstruction from genotype data using Imperfect Phylogeny. Bioinformatics. 2004;12:1842-1849.
-
(2004)
Bioinformatics
, vol.12
, pp. 1842-1849
-
-
Halperin, E.1
Eskin, E.2
-
44
-
-
70349432367
-
CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti
-
Leger P, Dillingham R, Beauharnais CA, et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis. 2009;6:955-964.
-
(2009)
J Infect Dis
, vol.6
, pp. 955-964
-
-
Leger, P.1
Dillingham, R.2
Beauharnais, C.A.3
-
45
-
-
65649091303
-
Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans
-
Haas DW, Gebretsadik T, Mayo G, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis. 2009;6:872-880.
-
(2009)
J Infect Dis
, vol.6
, pp. 872-880
-
-
Haas, D.W.1
Gebretsadik, T.2
Mayo, G.3
-
46
-
-
33646510761
-
Screening for polymorphisms in the PXR gene in a Dutch population
-
Bosch TM, Deenen M, Pruntel R, et al. Screening for polymorphisms in the PXR gene in a Dutch population. Eur J Clin Pharmacol. 2006;5:395-399.
-
(2006)
Eur J Clin Pharmacol
, vol.5
, pp. 395-399
-
-
Bosch, T.M.1
Deenen, M.2
Pruntel, R.3
-
47
-
-
0036219998
-
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations
-
Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002;2:121-132.
-
(2002)
Pharmacogenetics
, vol.2
, pp. 121-132
-
-
Lamba, J.K.1
Lin, Y.S.2
Thummel, K.3
-
48
-
-
0035197548
-
Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos
-
Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;3:825-831.
-
(2001)
J Pharmacol Exp Ther
, vol.3
, pp. 825-831
-
-
Dai, D.1
Tang, J.2
Rose, R.3
-
49
-
-
1642457182
-
Identification of a novel polymorphic enhancer of the human CYP3A4 gene
-
Matsumura K, Saito T, Takahashi Y, et al. Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol Pharmacol. 2004;2:326-334.
-
(2004)
Mol Pharmacol
, vol.2
, pp. 326-334
-
-
Matsumura, K.1
Saito, T.2
Takahashi, Y.3
-
51
-
-
27544486754
-
Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles
-
Rodriguez-Antona C, Sayi JG, Gustafsson LL, et al. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun. 2005;1:299-305.
-
(2005)
Biochem Biophys Res Commun
, vol.1
, pp. 299-305
-
-
Rodriguez-Antona, C.1
Sayi, J.G.2
Gustafsson, L.L.3
-
52
-
-
41149092923
-
Impact of CYP2B6 983T.C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
-
Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T.C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008;4: 914-918.
-
(2008)
J Antimicrob Chemother
, vol.4
, pp. 914-918
-
-
Wyen, C.1
Hendra, H.2
Vogel, M.3
-
53
-
-
58349108089
-
Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America
-
Kosoy R, Nassir R, Tian C, et al. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat. 2009;1:69-78.
-
(2009)
Hum Mutat
, vol.1
, pp. 69-78
-
-
Kosoy, R.1
Nassir, R.2
Tian, C.3
-
54
-
-
49949084478
-
Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication
-
Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther. 2008;5:675-685.
-
(2008)
Antivir Ther
, vol.5
, pp. 675-685
-
-
Stohr, W.1
Back, D.2
Dunn, D.3
-
55
-
-
40549097017
-
Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: Results of CPCRA 058 (FIRST Study)
-
Tedaldi EM, Absalon J, Thomas AJ, et al. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr. 2008;4:441-448.
-
(2008)
J Acquir Immune Defic Syndr
, vol.4
, pp. 441-448
-
-
Tedaldi, E.M.1
Absalon, J.2
Thomas, A.J.3
-
56
-
-
0035933511
-
The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity
-
Watkins RE, Wisely GB, Moore LB, et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science. 2001;5525:2329-2333.
-
(2001)
Science
, vol.5525
, pp. 2329-2333
-
-
Watkins, R.E.1
Wisely, G.B.2
Moore, L.B.3
-
57
-
-
33644588715
-
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz
-
Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006;3:191-198.
-
(2006)
Pharmacogenet Genomics
, vol.3
, pp. 191-198
-
-
Wang, J.1
Sonnerborg, A.2
Rane, A.3
-
58
-
-
0032766430
-
Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene
-
Kawamoto T, Sueyoshi T, Zelko I, et al. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol. 1999;9:6318-6322.
-
(1999)
Mol Cell Biol
, vol.9
, pp. 6318-6322
-
-
Kawamoto, T.1
Sueyoshi, T.2
Zelko, I.3
-
59
-
-
66649134127
-
Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay
-
Kozawa M, Honma M, Suzuki H. Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay. Drug Metab Dispos. 2009;6:1234-1241.
-
(2009)
Drug Metab Dispos
, vol.6
, pp. 1234-1241
-
-
Kozawa, M.1
Honma, M.2
Suzuki, H.3
-
60
-
-
34248573947
-
Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice
-
Molto J, Blanco A, Miranda C, et al. Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol. 2007;6:715-721.
-
(2007)
Br J Clin Pharmacol
, vol.6
, pp. 715-721
-
-
Molto, J.1
Blanco, A.2
Miranda, C.3
-
61
-
-
9144262579
-
CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation
-
Murayama N, Nakamura T, Saeki M, et al. CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation. Drug Metab Pharmacokinet. 2002;2:150-156.
-
(2002)
Drug Metab Pharmacokinet
, vol.2
, pp. 150-156
-
-
Murayama, N.1
Nakamura, T.2
Saeki, M.3
-
62
-
-
60349106806
-
The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density
-
Kang YS, Park SY, Yim CH, et al. The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther. 2009;3: 312-318.
-
(2009)
Clin Pharmacol Ther
, vol.3
, pp. 312-318
-
-
Kang, Y.S.1
Park, S.Y.2
Yim, C.H.3
-
63
-
-
0034959461
-
Identification and functional characterization of eight CYP3A4 protein variants
-
Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics. 2001;5:447-458.
-
(2001)
Pharmacogenetics
, vol.5
, pp. 447-458
-
-
Eiselt, R.1
Domanski, T.L.2
Zibat, A.3
-
65
-
-
84856916661
-
-
Accessed November 17, 2009
-
GeneCards Human Gene Database. Available at: http://www.genecards.org/ cgi-bin/carddisp.pl?gene=CYP3A4&search=rs4987159&snp=322&snp-sort- mode=140#snp. Accessed November 17, 2009.
-
GeneCards Human Gene Database
-
-
-
66
-
-
33947382259
-
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals
-
Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007;4:557-566.
-
(2007)
Clin Pharmacol Ther
, vol.4
, pp. 557-566
-
-
Rotger, M.1
Tegude, H.2
Colombo, S.3
-
67
-
-
33847348828
-
Does tenofovir influence efavirenz pharmacokinetics?
-
Rotger M, Colombo S, Furrer H, et al. Does tenofovir influence efavirenz pharmacokinetics? Antivir Ther. 2007;1:115-118.
-
(2007)
Antivir Ther
, vol.1
, pp. 115-118
-
-
Rotger, M.1
Colombo, S.2
Furrer, H.3
-
68
-
-
35348923463
-
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26
-
Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 2007;9:1230-1237.
-
(2007)
Clin Infect Dis
, vol.9
, pp. 1230-1237
-
-
Gatanaga, H.1
Hayashida, T.2
Tsuchiya, K.3
-
69
-
-
0037378823
-
Functional characterization of cytochrome P450 2B6 allelic variants
-
Jinno H, Tanaka-Kagawa T, Ohno A, et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos. 2003;4: 398-403.
-
(2003)
Drug Metab Dispos
, vol.4
, pp. 398-403
-
-
Jinno, H.1
Tanaka-Kagawa, T.2
Ohno, A.3
-
70
-
-
0142188754
-
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
-
Kirchheiner J, Klein C, Meineke I, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003;10:619-626.
-
(2003)
Pharmacogenetics
, vol.10
, pp. 619-626
-
-
Kirchheiner, J.1
Klein, C.2
Meineke, I.3
-
71
-
-
33750312905
-
Multilocus genetic interactions and response to efavirenz-containing regimens: An adult AIDS clinical trials group study
-
Motsinger AA, Ritchie MD, Shafer RW, et al. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics. 2006;11: 837-845.
-
(2006)
Pharmacogenet Genomics
, vol.11
, pp. 837-845
-
-
Motsinger, A.A.1
Ritchie, M.D.2
Shafer, R.W.3
-
72
-
-
67649126219
-
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART
-
Bertrand J, Treluyer JM, Panhard X, et al. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur J Clin Pharmacol. 2009;7:667-678.
-
(2009)
Eur J Clin Pharmacol
, vol.7
, pp. 667-678
-
-
Bertrand, J.1
Treluyer, J.M.2
Panhard, X.3
|